The Kv7 Modulator, Retigabine, is an Efficacious Antiseizure Drug for Delayed Treatment of Organophosphate-induced Status Epilepticus
| Autor: | Jay Spampanato, Kyle Berger, Cecelia E. Jackson, John H. McDonough, Hilary S. McCarren, F. Edward Dudek, Bryan S. Barker, David T. Yeung |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
business.industry General Neuroscience Retigabine Organophosphate Status epilepticus Pharmacology Neuroprotection 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine chemistry Soman medicine Midazolam Diisopropyl fluorophosphate medicine.symptom business 030217 neurology & neurosurgery medicine.drug Nerve agent |
| Zdroj: | Neuroscience. 463:143-158 |
| ISSN: | 0306-4522 |
| DOI: | 10.1016/j.neuroscience.2021.03.029 |
| Popis: | Benzodiazepines are the primary treatment option for organophosphate (OP)-induced status epilepticus (SE), but these antiseizure drugs (ASDs) lose efficacy as treatment is delayed. In the event of a mass civilian or military exposure, significant treatment delays are likely. New ASDs that combat benzodiazepine-resistant, OP-induced SE are critically needed, particularly if they can be efficacious after a long treatment delay. This study evaluated the efficacy of the Kv7 channel modulator, retigabine, as a novel therapy for OP-induced SE. Adult, male rats were exposed to soman or diisopropyl fluorophosphate (DFP) to elicit SE and monitored by electroencephalogram (EEG) recording. Retigabine was administered alone or adjunctive to midazolam (MDZ) at delays of 20- or 40-min in the soman model, and 60-min in the DFP model. Following EEG recordings, rats were euthanized and brain tissue was collected for Fluoro-Jade B (FJB) staining to quantify neuronal death. In the DFP model, MDZ + 15 mg/kg retigabine suppressed seizure activity and was neuroprotective. In the soman model, MDZ + 30 mg/kg retigabine suppressed seizures at 20- and 40-min delays. Without MDZ, 15 mg/kg retigabine provided partial antiseizure and neuroprotectant efficacy in the DFP model, while 30 mg/kg without MDZ failed to attenuate soman-induced SE. At 60 mg/kg, retigabine without MDZ strongly reduced seizure activity and neuronal degeneration against soman-induce SE. This study demonstrates the antiseizure and neuroprotective efficacy of retigabine against OP-induced SE. Our data suggest retigabine could be a useful adjunct to standard-of-care and has potential for use in the absence of MDZ. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect